Improving your

Understanding of Theranostics

Theranostics is a cutting-edge approach in modern medicine that combines diagnostic and therapeutic capabilities into a single integrated platform. By utilising molecular imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), theranostics enables clinicians to accurately diagnose diseases and assess their molecular characteristics. In addition to diagnosis, theranostics also involves the targeted delivery of therapeutic agents, such as radioactive isotopes or nanoparticles, to specific disease sites identified during imaging. This personalised treatment approach allows for precise and effective therapy tailored to individual patients, leading to improved outcomes and reduced side effects.

Theranostics represents a promising avenue for advancing precision medicine and transforming the way we diagnose and treat diseases.

What is Theranostics? A New Era of Precision Cancer Care

The word "theranostics" combines two concepts: therapy and diagnostics. Traditionally, diagnosing a disease and treating it have been separate processes. Theranostics brings these two elements together by using the same biological target to both identify cancer cells and deliver treatment directly to them. In simple terms, theranostics allows clinicians to locate cancer with remarkable precision and then use that information to guide a targeted treatment strategy.

Education

What to Expect from Theranostics Treatment

While every person's diagnosis and treatment plan is different, theranostics typically follows a structured pathway that combines advanced medical imaging with targeted treatment. Your treating specialists will guide you through each step based on your individual circumstances.

Patients

How Theranostics is Transforming Thyroid Cancer Treatment

Thyroid cancer develops when abnormal cells grow uncontrollably within the thyroid – a small, butterfly-shaped gland located at the base of the neck. The thyroid produces hormones that help regulate many important functions in the body, including metabolism, heart rate and body temperature.

Education

How Theranostics is Transforming Neuroendocrine Cancer Treatment

Neuroendocrine tumours, commonly known as NETs, are a diverse group of uncommon cancers that develop from neuroendocrine cells. These specialised cells are found throughout the body and share characteristics of both nerve cells and hormone-producing endocrine cells. NETs can behave very differently.

Cancer Types

How Theranostics is Transforming Prostate Cancer Treatment

Prostate cancer is one of the most advanced applications of theranostics today. PSMA-targeted imaging and therapy have significantly changed how advanced prostate cancer is diagnosed and treated.

Cancer Types

The Role of Theranostics in Modern Oncology Practice

Advances in molecular imaging, biomarker identification and targeted radionuclide therapies are enabling more personalised treatment approaches that can better characterise disease and inform therapeutic decision-making. Theranostics sits at the centre of this evolution.

General

The National Actinium-225 Survey: Understanding the Future of Actinium-Based Therapies

Oncothera Advocacy and the Radiopharma Initiative are calling on clinicians, researchers, institutions, CROs, regulators, and industry stakeholders to help shape the future of Actinium-based therapies. Your input and insights will help inform future advocacy, research priorities, infrastructure planning, and clinical readiness across the theranostics ecosystem. If you work in nuclear medicine, oncology, radiopharma, research, policy, and other related areas.

Research

Precision Medicine in Action: Driving NSW’s Theranostics Research & Clinical Future

An educational symposium hosted by Oncothera Advocacy, with the support of government and commercial partners. 21st March 2026, University of Sydney Oncothera Advocacy was proud to host Precision Medicine in Action: Driving NSW’s Theranostics Research & Clinical Future this past weekend at the University of Sydney, welcoming more than 65 attendees from across clinical, research, policy and industry sectors. The strong turnout and sustained engagement throughout the day refle

Patients

World Theranostics Day: Advancing Awareness, Empowering Patients

On World Theranostics Day, Oncothera Advocacy highlights the power of precision medicine to transform cancer care. Partnering with the Oncidium Foundation, we’re combining global momentum with a strong Australian, patient-first focus—raising awareness, improving access, and ensuring more patients benefit from theranostics.

News

Why Neutral Advocacy Matters in Emerging Therapies

Neutral advocacy means speaking up for what’s right – not what’s commercially convenient. It means putting patients, evidence and equity at the centre, rather than representing a single manufacturer, company, or commercial agenda.

Patients

Championing Patient Access to Theranostics in Australia: About Us

We’re excited to share the launch of the Oncothera Advocacy “About Us” flyer, a concise introduction to our mission: making theranostics...

General

Patients at the Heart: How Oncothera is Advancing Theranostics in Australia

Oncothera: A Patient-Centric Approach to Theranostics Patient-Centric Approach to Theranostics At Oncothera, we believe that patients should be at the core of every decision in the theranostics landscape. As a registered charity, our mission is to advocate for better patient access, foster collaboration among key industry players, and drive awareness for the life-changing potential of theranostic treatments. Through education, debate, and strategic partnerships, we aim to cre

General

Oncothera recognises World Theranostics Day

World Theranostics Day: Recognising Oncothera’s Mission and the People Behind It

World Theranostics Day: 31st March 2025 On this #WorldTheranosticsDay, we take a moment to reflect on the growing impact of theranostics in transforming cancer care. Today is also an opportunity to acknowledge the dedicated individuals leading Oncothera, a not-for-profit registered charity founded in early 2024. Our Mission: Expanding Access to Theranostics in Australia Oncothera was established with a clear and urgent purpose—to improve access for Australian patients to cutt

News